This bill aims to prohibit the use of step therapy protocols for prescription insulin drugs within health plans that cover diabetes treatment. It introduces new legal language under Minnesota Statutes, specifically in chapter 62Q, which defines key terms related to diabetes and step therapy protocols. The bill mandates that health plans cannot limit or exclude coverage for insulin drugs by imposing step therapy requirements, ensuring that patients have direct access to necessary medications. The prohibition is set to take effect on January 1, 2027, applying to health plans offered, issued, or renewed after that date.

Additionally, the bill amends Minnesota Statutes 2024, section 256B.0625, subdivision 13f, to align with the new prohibition on step therapy for insulin. It specifies that any step therapy protocol requirements established by the commissioner must comply with the newly inserted sections 62Q.1841 and 62Q.1842. The effective date for this amendment is also set for January 1, 2027, or upon federal approval, whichever is later. This legislative change aims to enhance patient access to insulin treatments and streamline the prior authorization process for medications related to diabetes care.

Statutes affected:
Introduction: 256B.0625